Modified GRF (1–29) / GHRP-2 Blend is a research peptide formulation combining two well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: Modified GRF (1–29) and Growth Hormone–Releasing Peptide-2 (GHRP-2). Modified GRF (1–29) is a stabilized analog of growth hormone–releasing hormone (GHRH), while GHRP-2 is a potent growth hormone secretagogue receptor (GHS-R) agonist. Together, this blend is formulated for laboratory research focused on pulsatile growth hormone release, receptor signaling pathways, and coordinated endocrine response mechanisms.
Prior to the targeted synthesis and study of these peptides, research into growth hormone modulation relied largely on less selective secretagogues and broader hormonal interventions. In controlled research settings, Modified GRF (1–29) has been studied for its ability to stimulate endogenous growth hormone release through GHRH receptor activation while maintaining a short duration of activity. GHRP-2 has been widely researched for its strong receptor binding affinity and its influence on growth hormone secretion dynamics. The combination allows researchers to examine complementary mechanisms involved in growth hormone pulsatility, secretion amplitude, and signaling coordination.
Currently, the Modified GRF (1–29) / GHRP-2 Blend is being investigated for potential applications in metabolic research models, endocrine pathway analysis, recovery-related signaling studies, and age-associated hormone regulation research. Additional investigation continues into its role in downstream anabolic signaling, circadian hormone release patterns, and integrated pituitary response mechanisms. Due to the complementary research interest of these peptides, this blend remains a compelling subject for ongoing laboratory investigation.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
The Modified GRF (1-29), GHRP-2 Blend is designed for laboratory research investigating growth hormone signaling pathways, endocrine communication within the hypothalamic–pituitary axis, and downstream metabolic biomarker responses. By combining a growth hormone–releasing hormone analog with a growth hormone secretagogue, this blend allows researchers to examine how complementary signaling pathways influence pulsatile hormone release patterns in controlled experimental environments.
Multi-peptide research models are frequently used to evaluate interactions between upstream hypothalamic signaling and pituitary hormone response mechanisms. Because blended peptide protocols introduce multiple signaling inputs, experimental frameworks typically emphasize strict control conditions, standardized sampling intervals, and detailed protocol documentation to maintain reproducibility across research studies.
Modified GRF (1-29), GHRP-2 Blend – Research Specifications:
| Format | Lyophilized peptide blend (research format) |
| Contents | Modified GRF (1-29) + GHRP-2 |
| Purity / Identity | Research-grade; refer to Certificate of Analysis (COA) for lot-specific analytical data |
| Source | Peptide synthesis with standardized processing and QC documentation |
| Appearance | Powder (lyophilized) |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture. Maintain lot integrity per laboratory SOPs. |
| Research Use Only | Supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
Modified GRF (1-29), often referenced in peptide research as a growth hormone–releasing hormone analog, is studied in laboratory environments examining pulsatile growth hormone release and hypothalamic– pituitary communication. The compound is designed to interact with receptors involved in growth hormone regulation, making it useful in experiments that analyze endocrine signaling behavior.
GHRP-2 is a growth hormone secretagogue commonly studied for its interaction with ghrelin receptor pathways. In research models, this peptide is often used to examine pituitary signaling responses and downstream endocrine marker fluctuations associated with growth hormone activity.
When these two peptides are combined in experimental protocols, investigators can evaluate how GHRH pathway stimulation interacts with ghrelin receptor–mediated signaling. Some research designs measure hormone pulse amplitude, frequency, and associated biomarker responses in order to better understand endocrine pathway dynamics.
Researchers examining the peptides individually can also reference the product pages for CJC-1295 (without DAC) (commonly associated with Modified GRF research) and GHRP-2.
Important Research Notice: Nordsci products are supported by lot-level analytical documentation. Certificates of Analysis are available to support internal audits, method alignment, and reproducibility across research studies.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
One of the primary research applications for this peptide blend is examining pulsatile growth hormone signaling. Investigators may monitor endocrine marker changes across defined sampling windows to observe how combined pathway activation influences hormone release patterns.
Because Modified GRF (1-29) and GHRP-2 interact with different components of the GH-axis signaling pathway, laboratories may evaluate how hypothalamic signals and pituitary responses communicate within endocrine regulatory systems.
Researchers often measure downstream biomarkers when studying GH-axis signaling. In controlled research environments, investigators may analyze endocrine marker changes associated with hormone signaling fluctuations triggered by peptide pathway activation.
Some experimental frameworks compare blended peptide protocols with single-peptide conditions. This approach allows researchers to determine whether observed signaling effects arise from individual pathways or the interaction of multiple endocrine signaling inputs.
The Modified GRF (1-29), GHRP-2 Blend should be handled according to standard peptide laboratory procedures emphasizing contamination prevention, proper storage conditions, and thorough experimental documentation. Maintaining stable laboratory environments helps ensure reliable experimental outcomes.
Protocol Design Considerations: Growth hormone signaling research is sensitive to circadian rhythm timing, metabolic state, environmental conditions, and stress variables. Carefully controlled laboratory environments and standardized sampling windows help maintain reproducibility across research cohorts.
Note: The information above is provided solely as a research reference summary. All experimental work must be conducted by qualified researchers in appropriate laboratory facilities.
Each lot of this peptide blend is supported by a Certificate of Analysis verifying peptide identity and quality parameters. These analytical reports assist laboratories with procurement verification, documentation compliance, and reproducibility tracking across research studies.
Laboratories sourcing peptides for endocrine signaling research typically prioritize traceable documentation, reliable synthesis standards, and strict quality-control procedures. Nordsci Peptides provides research-grade peptide materials supported by analytical documentation and manufacturing protocols designed to support reproducible laboratory research.
IMPORTANT: This product is supplied exclusively for laboratory research use. It is not approved for human consumption or clinical application. Researchers are responsible for ensuring compliance with all applicable regulatory and institutional guidelines.
